Tall stature is less often experienced as an important problem than short stature. However, a correct diagnosis may be of eminent importance, especially when interventions are planned, or to know the natural history. Overgrowth can be caused by endocrine disorders and skeletal dysplasias, but also by several genetic syndromes. Despite a systematic diagnostic approach, there will be patients with tall stature who do not fit a known diagnosis. In this group of patients possibilities of genetic analysis do exist, but are not common practice. The FMR1 gene should be analyzed in patients with tall stature and mental retardation, and in these patients the NSD1 gene can be considered whenever some features of Sotos syndrome do exist. In tall patients without mental retardation and some features of Sotos or Beckwith-Wiedemann syndrome it may still be useful to look for mutations in the NSD1 gene, but also for changes in the 11p15 region. The various possibilities are discussed and placed in a flowchart.

Keywords:
Tall stature, Growth, Genes, Genetics
1.
Teasdale TW, Owen DR, Sorensen TI: Intelligence and educational level in adult males at the extremes of stature. Hum Biol 1991;63:19–30.
2.
Cassidy CM: The good body: when big is better. Med Anthropol 1991;13:181–213.
3.
Leung AK, Robson WL: Evaluating tall children. Can Fam Physician 1995;41:457–458, 461–462, 465–468.
4.
Lecointre C, Toublanc JE: Psychological indications for treatment of tall stature in adolescent girls. J Pediatr Endocrinol Metab 1997;10:529–531.
5.
Drop SL, Greggio N, Cappa M, Bernasconi S: International Workshop on Management of Puberty for Optimum Auxological Results. Current concepts in tall stature and overgrowth syndromes. J Pediatr Endocrinol Metab 2001;14(suppl 2):975–984.
6.
Sotos JF: Overgrowth. Section I. Overgrowth disorders. Clin Pediatr (Phila) 1996;35:517–529.
7.
Cuttler L: Evaluation of growth disorders in children. Pediatrician 1987;14:109–120.
8.
Drop SL, De Waal WJ, De Muinck Keizer- Schrama SM: Sex steroid treatment of constitutionally tall stature. Endocr Rev 1998;19:540–558.
9.
Cohen MM Jr: Overgrowth syndromes: an update. Adv Pediatr 1999;46:441–491.
10.
Ambler G: Overgrowth. Best Pract Res Clin Endocrinol Metab 2002;16:519–546.
11.
Ranke MB: The KIGS aetiology classification system; in Ranke MB, Gunnarsson R (eds): Progress in Growth Hormone Therapy – 5 Years of KIGS. Mannheim, J&J Verlag, 1994, pp 51–61.
12.
Ranke MB: Towards a consensus on the definition of idiopathic short stature. Horm Res 1996;45(suppl 2):64–66.
13.
Zachmann M: Diagnosis of treatable types of short and tall stature. Postgrad Med J 1978;54(suppl 1):121–132.
14.
Heinrich UE: Intrauterine growth retardation and familial short stature. Baillières Clin Endocrinol Metab 1992;6:589–601.
15.
Ogata T, Matsuo N, Nishimura G: SHOX haploinsufficiency and overdosage: impact of gonadal function status. J Med Genet 2001;38:1–6.
16.
Sotos JF: Overgrowth. Section IV. Genetic disorders associated with overgrowth. Clin Pediatr (Phila) 1997;36:39–49.
17.
Cohen MM Jr, Neri G, Weksberg R: Overgrowth Syndromes, ed 1. Oxford/New York, Oxford University Press, 2002.
18.
Okubo Y, Siddle K, Firth H, O’Rahilly S, Wilson LC, Willatt L, Fukushima T, Takahashi S, Petry CJ, Saukkonen T, Stanhope R, Dunger DB: Cell proliferation activities on skin fibroblasts from a short child with absence of one copy of the type 1 insulin-like growth factor receptor (IGF1R) gene and a tall child with three copies of the IGF1R gene. J Clin Endocrinol Metab 2003;88:5981–5988.
19.
Weksberg R, Smith AC, Squire J, Sadowski P: Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development. Hum Mol Genet 2003;12:R61–R68.
20.
Gyftodimou J, Karadima G, Pandelia E, Vassilopoulos D, Petersen MB: Angelman syndrome with uniparental disomy due to paternal meiosis II nondisjunction. Clin Genet 1999;55:483–486.
21.
Fridman C, Varela MC, Nicholls RD, Koiffmann CP: Unusual clinical features in an Angelman syndrome patient with uniparental disomy due to a translocation 15q15q. Clin Genet 1998;54:303–308.
22.
Bleasel JF, Holderbaum D, Mallock V, Haqqi TM, Williams HJ, Moskowitz RW: Hereditary osteoarthritis with mild spondyloepiphyseal dysplasia – are there ‘hot spots’ on COL2A1? J Rheumatol 1996;23:1594–1598.
23.
Hamersma H, Gardner J, Beighton P: The natural history of sclerosteosis. Clin Genet 2003;63:192–197. Erratum in Clin Genet 2003;64:176.
24.
Wraith JE: The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Child 1995;72:263–267.
25.
Barone R, Nigro F, Triulzi F, Musumeci S, Fiumara A, Pavone L: Clinical and neuroradiological follow-up in mucopolysaccharidosis type III (Sanfilippo syndrome). Neuropediatrics 1999;30:270–274.
26.
Hall CM: International nosology and classification of constitutional disorders of bone (2001). Am J Med Genet 2002;113:65–77.
27.
Sotos JF: Overgrowth. Section II. Hormonal Causes. Clin Pediatr (Phila) 1996;35:579–590.
28.
Schoof E, Dorr HG, Kiess W, Ludecke DK, Freitag E, Zindel V, Rascher W, Dotsch J: Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism – effect of octreotide therapy. Horm Res 2004;61:184–189.
29.
Lumbroso S, Paris F, Sultan C: Activating Gsα mutations: analysis of 113 patients with signs of McCune-Albright syndrome – a European Collaborative Study. J Clin Endocrinol Metab 2004;89:2107–2113.
30.
Themmen AP, Verhoef-Post M: LH receptor defects. Semin Reprod Med 2002;20:199–204.
31.
Richter-Unruh A, Martens JW, Verhoef-Post M, Wessels HT, Kors WA, Sinnecker GH, Boehmer A, Drop SL, Toledo SP, Brunner HG, Themmen AP: Leydig cell hypoplasia: cases with new mutations, new polymorphisms and cases without mutations in the luteinizing hormone receptor gene. Clin Endocrinol (Oxf) 2002;56:103–112.
32.
Frank GR: Role of estrogen and androgen in pubertal skeletal physiology. Med Pediatr Oncol 2003;41:217–221.
33.
Munns CF, Batch JA: Hyperinsulinism and Beckwith-Wiedemann syndrome. Arch Dis Child Fetal Neonatal Ed 2001;84:F67–69.
34.
Niemitz EL, DeBaun MR, Fallon J, Murakami K, Kugoh H, Oshimura M, Feinberg AP: Microdeletion of LIT1 in familial Beckwith- Wiedemann syndrome. Am J Hum Genet 2004;75:844–849.
35.
Sparago A, Cerrato F, Vernucci M, Ferrero GB, Silengo MC, Riccio A: Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome. Nat Genet 2004;36:958–960.
36.
Morisson IM, Reeve, AE: Insulin-like growth factor 2 and overgrowth: molecular biology and clinical implications. Mol Med Today 1998;4:110–115.
37.
Elias LL, Huebner A, Metherell LA, Canas A, Warne GL, Bitti ML, Cianfarani S, Clayton PE, Savage MO, Clark AJ: Tall stature in familial glucocorticoid deficiency. Clin Endocrinol (Oxf) 2000;53:423–430.
38.
Savage MO, Lebrethon MC, Blair JC, Ho JT, Johnston LB, Lienhardt A, Clark AJ, Chaussain JL: Growth abnormalities associated with adrenal disorders and their management. Horm Res 2001;56(suppl 1):19–23.
39.
Neri G, Gurrieri F, Zanni G, Lin A: Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. Am J Med Genet 1998;79:279–283.
40.
Mariani S, Iughetti L, Bertorelli R, Coviello D, Pellegrini M, Forabosco A, Bernasconi S: Genotype/phenotype correlations of males affected by Simpson-Golabi-Behmel syndrome with GPC3 gene mutations: patient report and review of the literature. J Pediatr Endocrinol Metab 2003;16:225–232.
41.
Veugelers M, Vermeesch J, Watanabe K, Yamaguchi Y, Marynen P, David G: GPC4, the gene for human K-glypican, flanks GPC3 on xq26: deletion of the GPC3-GPC4 gene cluster in one family with Simpson-Golabi-Behmel syndrome. Genomics 1998;53:1–11.
42.
Li M, Shuman C, Fei YL, Cutiongco E, Bender HA, Stevens C, Wilkins-Haug L, Day-Salvatore D, Yong SL, Geraghty MT, Squire J, Weksberg R: GPC3 mutation analysis in a spectrum of patients with overgrowth expands the phenotype of Simpson-Golabi-Behmel syndrome. Am J Med Genet 2001;102:161–168.
43.
Douglas J, Hanks S, Temple IK, Davies S, Murray A, Upadhyaya M, Tomkins S, Hughes HE, Cole TR, Rahman N: NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes. Am J Hum Genet 2003;72:132–143.
44.
Rio M, Clech L, Amiel J, Faivre L, Lyonnet S, Le Merrer M, Odent S, Lacombe D, Edery P, Brauner R, Raoul O, Gosset P, Prieur M, Vekemans M, Munnich A, Colleaux L, Cormier-Daire V: Spectrum of NSD1 mutations in Sotos and Weaver syndromes. J Med Genet 2003;40:436–440.
45.
De Boer L, Kant SG, Karperien M, Van Beers L, Tjon J, Vink GR, Van Tol D, Dauwerse H, Le Cessie S, Beemer FA, Van Der Burgt I, Hamel BC, Hennekam RC, Kuhnle U, Mathijssen IB, Veenstra-Knol HE, Schrander Stumpel CT, Breuning MH, Wit JM: Genotype-phenotype correlation in patients suspected of having Sotos syndrome. Horm Res 2004;62:197–207.
46.
Robinson PN, Booms P, Katzke S, Ladewig M, Neumann L, Palz M, Pregla R, Tiecke F, Rosenberg T: Mutations of FBN1 and genotype-phenotype correlations in Marfan syndrome and related fibrillinopathies. Hum Mutat 2002;20:153–161.
47.
Tiecke F, Katzke S, Booms P, Robinson PN, Neumann L, Godfrey M, Mathews KR, Scheuner M, Hinkel GK, Brenner RE, Hovels-Gurich HH, Hagemeier C, Fuchs J, Skovby F, Rosenberg T: Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype-phenotype correlations in FBN1 exons 24–40. Eur J Hum Genet 2001;9:13–21.
48.
Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R, Fowler B, Grobe H, Schmidt H, Schweitzer L: The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1985;37:1–31.
49.
Gaustadnes M, Wilcken B, Oliveriusova J, McGill J, Fletcher J, Kraus JP, Wilcken DE: The molecular basis of cystathionine β-synthase deficiency in Australian patients: genotype-phenotype correlations and response to treatment. Hum Mutat 2002;20:117–126.
50.
Loesch DZ, Huggins RM, Hoang NH: Growth in stature in fragile X families: a mixed longitudinal study. Am J Med Genet 1995;58:249–256.
51.
Sutherland GR, Hecht F: The fragile-X syndrome: physical phenotype; in Fragile Sites on Human Chromosomes. New York, Oxford University Press, 1985, pp 132–49.
52.
De Vries BB, Robinson H, Stolte-Dijkstra I, Tjon Pian Gi CV, Dijkstra PF, van Doorn J, Halley DJ, Oostra BA, Turner G, Niermeijer MF: General overgrowth in the fragile X syndrome: variability in the phenotypic expression of the FMR1 gene mutation. J Med Ge net 1995;32:764–769.
53.
Iughetti L, Bergomi A, Bernasconi S: Diagnostic approach and therapy of overgrowth and tall stature in childhood. Minerva Pediatr 2003;55:563–582.
54.
Baujat G, Rio M, Rossignol S, Sanlaville D, Lyonnet S, Le Merrer M, Munnich A, Gicquel C, Cormier-Daire V, Colleaux L: Paradoxical NSD1 mutations in Beckwith-Wiedemann syndrome and 11p15 anomalies in Sotos syndrome. Am J Hum Genet 2004;74:715–720.
55.
Neri G, Steindl K, Mazzei A, Battaglia A, Cappa M: Nonsyndromal overgrowth in males with mild psychomotor delay. Am J Med Genet 1998;79:291–293.
56.
Turkmen S, Gillessen-Kaesbach G, Meinecke P, Albrecht B, Neumann LM, Hesse V, Palanduz S, Balg S, Majewski F, Fuchs S, Zschieschang P, Greiwe M, Mennicke K, Kreuz FR, Dehmel HJ, Rodeck B, Kunze J, Tinschert S, Mundlos S, Horn D: Mutations in NSD1 are responsible for Sotos syndrome, but are not a frequent finding in other overgrowth phenotypes. Eur J Hum Genet 2003;11:858–865.
57.
Niikawa N, Ishikiriyama S, Takahashi S, Inagawa A, Tonoki H, Ohta Y, Hase N, Kamei T, Kajii T: The Wiedemann-Beckwith syndrome: pedigree studies on five families with evidence for autosomal dominant inheritance with variable expressivity. Am J Med Genet 1986;24:41–55.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.